title: Different therapeutic and bystander effects by intranasal administration of homologous type II and type IX collagens on the collagen-induced arthritis and pristane-induced arthritis in rats.
abstract: To assess the efficiency of nasally administered cartilage-specific collagens as vaccination against development of arthritis and to ameliorate already established chronic arthritis, experimental models which develop chronic arthritis, pristane-induced arthritis (PIA), and homologous collagen-induced arthritis (CIA) in the rat were selected. Cartilage-specific collagens type IX (CIX) and type II (CII) were used for vaccination intranasally. A single dose of 250 microg CII instilled intranasally in rats with established PIA ameliorated the disease. For the prevention of disease, the same dose given before immunization was found to be most effective. Most importantly, the disease was more severe if this dose was given three times. For treatment of PIA, CIX was found to be more effective than CII, whereas for treatment of CIA only CII was effective. The amelioration of CIA was associated with a marked suppression of delayed type hypersensitivity and the flare reaction to CII and lower levels of IgG2b anti-CII antibodies in serum, i.e., with suppression of the TH1 rather than the TH2 response to CII. These findings, that cartilage proteins, if given intranasally, can both prevent and ameliorate established chronic arthritis in rats, are of significant importance for possible use in rheumatoid arthritis. The identification of two different cartilage-specific proteins (CII and CIX) effective against a disease induced with a well-defined nonimmunogenic adjuvant such as pristane will be of value for enhancing the effectiveness of the treatment.
authors.affiliation: Department of Cell and Molecular Biology, Lund University, Lund, S-22100, Sweden.
authors.forename: S
authors.initials: S
authors.lastname: Lu
authors.forename: R
authors.initials: R
authors.lastname: Holmdahl
mesh_terms: D000281:Administration, Intranasal; D000818:Animals; D001169:Arthritis, Experimental / Q000188:drug therapy* / Q000276:immunology / Q000517:prevention & control; D003094:Collagen / Q000008:administration & dosage* / Q000276:immunology / Q000633:toxicity; D004195:Disease Models, Animal; D007166:Immunosuppressive Agents / Q000276:immunology / Q000633:toxicity*; D051381:Rats; D011917:Rats, Inbred Lew; D012680:Sensitivity and Specificity; D013729:Terpenes / Q000276:immunology / Q000633:toxicity*; D018417:Th1 Cells / Q000187:drug effects / Q000276:immunology; D014611:Vaccination
chemical_list: D007166:Immunosuppressive Agents; D013729:Terpenes; C009042:pristane; D003094:Collagen